To provide accessible and innovative genetic technologies, products and services for all.
Sansure Biotech Inc. is an in vitro diagnostic solution provider integrating diagnostic reagents,
instruments and independent clinic laboratory services with its own innovative gene technology as its core.
The company is committed to becoming a genetic technology provider, and is a National Demonstration Centre for the Application of Genetic Testing Technology and a National Joint Local Engineering Research Center for Genetic Diagnosis of Infection Diseases and Tumours.
Headquartered in Changsha, the company has built the new Industrial Park in Shanghai to create a
production base for precise and intelligent molecular diagnostic systems and an important international hub,
and set up branches or affiliates in nearly 20 cities, including Beijing, Guangzhou, Chongqing and Xi'an.
The company has developed a series of internationally leading core technologies and more than 500 products
with performance exceeding the advanced level at home and abroad. All of the new technologies and products
have lead the domestic industry to catch up with the international advanced level, and is now breaking the
monopoly of imports and promoting the application of gene technology from individual departments to multiple
departments in medical institutions, from high-end laboratories in large hospitals to all levels of
hospitals including primary medical institutions, and from a few fields to all scenarios.
Mission Statement
“Innovating Diagnostics For All” is more than merely just a mission statement. These four words represent a commitment and firm belief in revolutionizing the healthcare industry, improving patient outcomes, and fostering healthcare equity on a global scale. This mission goes beyond technological innovation to address broader societal needs and contribute to positive social change.
At Sansure, innovation is a core value. With a quickly growing list of patented technologies including one-tube fast release technology and superparamagnetic nano-bead technology, the company has developed hundreds of products employing internationally leading core technologies in the biotechnology industry. We are dedicated to ongoing research and development with the goal of early detection and disease prevention— early diagnosis not only leads to more effective treatment, but also reduces the burden on healthcare systems and improves patient outcomes. On a larger scale, we are conscious of the importance of early detection and management of infectious diseases in public health preparedness, striving to support timely public health responses. To us, each and every diagnosis represents a responsibility to the health of a patient and in many cases, of the greater community.
At the forefront, Sansure is committed to its social impact. Spanning medical institutions to laboratories of developed and developing regions alike, we endeavor to promote global accessibility and healthcare equity. With the ultimate goal of universal access to healthcare, Sansure aims to develop more affordable, efficient, and scalable solutions while never sacrificing quality and precision. These continuously improving and accessible diagnostic tools allow Sansure to continue to bridge gaps in healthcare delivery and reach the underserved populations that need us the most.
Innovating Diagnostics for All
In today's rapidly evolving healthcare landscape, biotechnology is a key player in advancing diagnostic capabilities. Biotech companies constantly strive for innovation, seeking to improve the accuracy, accessibility, and affordability of diagnostic tests, ensuring efficient healthcare delivery to populations in need.
The slogan "Innovating Diagnostics for All" embodies Sansure's commitment to promoting accessibility and equity in healthcare. Diagnostic kits aim to bridge the gap between developed and developing regions, urban and rural areas, and diverse socioeconomic backgrounds. By creating cost-effective, user-friendly, and scalable tests, biotech companies remove barriers that impede timely and accurate diagnoses. "For all" represents Sansure's aspiration to ensure that individuals from all walks of life can benefit from their improved diagnostic solutions.
The slogan also encompasses Sansure's dedication to advancing disease detection and prevention strategies. Through prioritized research and development, these companies continuously strive to enhance the accuracy of their kits in identifying pathogens, diagnosing diseases, and safeguarding one's health. Proactive disease detection leads to improved treatment outcomes and reduced healthcare costs. Additionally, innovative diagnostic solutions contribute to public health initiatives, exemplifying a commitment to improving population health and lessening the burden of diseases worldwide.
The term "innovation" reflects the dedication to developing solutions that optimize patients' well-being in the face of health crises. This is exemplified by advanced technologies utilized in diagnostic testing, employing techniques that enhance sensitivity, specificity, and speed.
Milestone
Sansure Biotech Inc . established Reagent productline starting
Developed the world's leading high precision Advanced Magnetic-beads technology
Developed world first class high precise Hepatitis B Nucleic Acid Diagnosis kit
Developed the world's leading fast and simple One-tube Fast Release Technology
Selected as a national high tech enterprise
Launched the automated instrument product line
Foundation construction of Sansure Biotech community
Selected as one of the top 100 growth startups in China Overseas Students Pioneer Community
Launched the blood screening product line
Developed Magnetic beads automated nucleic acid extract systems
Undertaken the national "863 Plan" and the national "12th Five Year Plan" major science and technology
special projects
Launched Gene Sequencing Product Line
Established Sanway Independent Clinic Laboratory
Approved as Hunan Provincial Engineering Research Centre for Nucleic Acid Diagnostic Technology
Liu Yandong, previous Vice Premier, visited Sansure
Approved as Hunan Provincial Engineering Research Centre for Nucleic Acid Diagnostic Technology
Won the second prize of National Science and Technology Progress Award
Established of POCT, Liquid Chip and Multiplex PCR Technology Platform
Approved to be National Demonstration Center for Gene Detection Technology Application
Global leading Universal Automatic Nucleic Acid Extraction System launched
More than 77 million US dollar of strategic investment was introduced
Approved to be National Joint Research Center for Infectious Diseases and Cancer Gene Diagnosis Technology
Dr. Dai Lizhong, Chairman of Sansure Biotech, was elected member of the National People's Congress
Approved to set up National Post-doctoral Research Workstation
Sansure Biotech Shanghai Co., Ltd. was founded to accelerate the pace of globalization
HPV detection reagents won the gold award of Excellent Innovative Products in In-vitro Diagnostics in China
Released Hypersensitive hepatitis, STD triple test and other products
Launched RNA One-tube Fast Release Technology, Meta-genome Sequencing and other technology platforms
Listed on Science and Technology Innovation Board of Shanghai Stock Exchange
Released SARS-CoV2 Nucleic Acid Detection Reagents on the global market (NMPA of China, US FDA, Australian TGA, Brazilian ANVISA, CE, EUA certificate etc.)
Released Hand-foot-mouth Triple Nucleic Acid Triple Test Reagent
Selected as a sample stock of "Technology 50" Index, get in the "Top 100 Chinese Pharmaceutical Industry List"
Acquired shares of GeneMind Biosciences Co, laying out the upstream of gene sequencing equipment
Six Respiratory Pathogens Nucleic Acid Diagnostic Kit, iPonatic Portable Nucleic Acid Detection Workstation(Four channels) launched
"Second Increasing Stage" to a world-class enterprise
HPV (13+2), Adenovirus, and Six respiratory pathogens (bacteria) nucleic acid diagnostic kits were released to the international market
Four NAT products for HBV, HCV, HIV, and blood screening obtained CE List A approval, respectively (the first in China and the second in the world)
